To report an adverse event or product quality complaint, call 1-877-TAKEDA-7 (1-877-825-3327)
To report an adverse event or product quality complaint, call 1-877-TAKEDA-7 (1-877-825-3327)
Not an actual patient.
Signs and symptoms of MMN include weakness in the hands, lower arms, and the lower limbs. Patients may experience cramping, involuntary contractions or twitching, and wasting of affected muscles.1 MMN is commonly misdiagnosed, which can lead to inappropriate treatment and progression of muscle weakness and/or disability.3,4,5,6,7
In the U.S., the prevalence of MMN is approximately 1 to 2 cases per 100,000 people, and the disease can mimic the early symptoms of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease), although it only has a third of the prevalence of ALS.3,8,9,10
First symptoms appear before the age of 50 in almost 80% of patients, with the mean age of onset at 40 years (range 20 to 70 years).3 Men are 2.7 times more likely to be affected by MMN than women.6
The exact mechanism of the disease is unknown.3 It is hypothesized that the slowed or faulty nerve conduction in MMN is due to demyelination of the myelin sheath or injury to the nerve itself by:3,13
Conduction block (CB) is the characteristic finding in MMN and is believed to be the underlying electrophysiological cause of muscle weakness.4 However, axon loss rather than CB is the most important determinant of permanent weakness and disability.3
The diagnosis of MMN requires clinical weakness without objective sensory loss and without upper motor neuron signs:5,11
Normal results are required for sensory nerve conduction studies.5 Laboratory and electrodiagnostic tests may help confirm the diagnosis but may not be definitive:3
A differential diagnosis is necessary to differentiate MMN from diseases with similar symptoms, such as ALS and chronic inflammatory demyelinating polyneuropathy (CIDP).3,4,5 Even with an accurate diagnosis, treatment options for MMN are limited and are aimed at modulating the aberrant immune responses.4,11,14,15
The goals of treatment are to:
Reverse motor CB15
Limit damage to axons to prevent permanent nerve damage8,15
Limit damage to myelin sheath and mitigate impaired signal conduction in nerves3,11
This is not intended to be a comprehensive resource of all congresses and congress materials across therapeutic and disease areas. Congress materials may include information about investigational use(s) of compounds/products that are not approved for use by the U.S. Food and Drug Administration (FDA) and/or are inconsistent with the Prescribing Information. Takeda does not recommend the use of any Takeda product beyond the approved labeling. Any decisions regarding the usage of a Takeda product beyond the approved labeling are left to the discretion of the healthcare professional. Takeda makes no representations about whether investigational compounds or unapproved uses will be approved by the FDA.
Premier global educational event for allergists and immunologists, with thousands of attendees each year, discussing allergies, asthma, and immune deficiency disorders.
Each year, the American Academy of Neurology's Annual Meeting offers a robust lineup of diverse learning opportunities covering nearly every topic and subspecialty, helping you stay up to date on the latest trusted science and essential education.
Brings together home and alternate site infusion professionals for four days of networking, education, and exhibits. The expo features companies displaying the latest products and services supporting the industry.
Global meeting featuring thought leaders from around the world focused on advancing patient care in allergy and immunology.
Annual meeting dedicated to the advancement of neuromuscular, musculoskeletal, and electrodiagnostic medicine.
Annual event with more than 2,500 members and non-members of the AMCP to engage on the latest innovations and most intentional networking in managed care pharmacy.
National conference of IgNS bringing together professionals and practitioners from all disciplines and clinical specialties to advance Ig therapy practice, while providing networking and comprehensive education opportunities.
This event brings together over 1200 HAE community members, including families, caregivers, healthcare professionals, and pharmaceutical representatives.
Regional annual conference discussing the most current information from top experts in allergy, asthma, and immunology.
International conference showcasing the latest advances in pulmonary disease, critical illness, and sleep disorders for scientists and clinicians at all stages of their careers.
Annual meeting with the goal of providing a stimulating forum with presentations and discussions on the latest advances in clinical immunology, including primary immunodeficiencies and immune dysregulatory diseases.
Annual meeting in neurology promoting high quality patient-centric care in a variety of topics and specialties through various learning formats.
Large assembly of pharmacy and healthcare professionals dedicated to the issues of managed care pharmacy, offering immersive education sessions and keynote presentations.
Annual conference ideal for infusion professionals or those seeking opportunities in the industry to come together and explore the latest trends in offering home-based services.
Premier global educational event for allergists and immunologists, with thousands of attendees each year, discussing allergies, asthma, and immune deficiency disorders.
Annual scientific session uniting allergists, immunologists, nurses, and physician assistants aimed at maintaining the highest standard of practice in allergy care.
Find materials to help foster a deeper understanding of Multifocal Motor Neuropathy (MMN).
An overview of Multifocal Motor Neuropathy (MMN) clinical presentation and diagnostic considerations.
An overview of the task force guideline recommendations for diagnosing Multifocal Motor Neuropathy (MMN).
This resource provides information on Takeda medications available in the Multifocal Motor Neuropathy category and is not intended to represent a complete list of therapeutic options.
[Immune Globulin Infusion (Human)] 10%
Click the button below to send us your Medical Inquiry. We are committed to responding to your inquiries, and will get back to you as soon as possible.
Contact us using the number below to: